top of page

FDA Requests Removal of All Ranitidine Products (Zantac) from the Market

Writer's picture: Pat OdinaPat Odina

For Immediate Release: April 01, 2020

The U.S. Food and Drug Administration today announced it is requesting manufacturers withdraw all prescription and over-the-counter (OTC) ranitidine drugs from the market immediately. This is the latest step in an ongoing investigation of a contaminant known as N-Nitrosodimethylamine (NDMA) in ranitidine medications (commonly known by the brand name Zantac). The agency has determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures and may result in consumer exposure to unacceptable levels of this impurity. As a result of this immediate market withdrawal request, ranitidine products will not be available for new or existing prescriptions or OTC use in the U.S.


9 views0 comments

Recent Posts

See All

Instagram

Comments


Commenting has been turned off.
bottom of page